Article Text

27 High definition lipoproteomics reveal dysregulated redox proteins in coronary artery disease
  1. Sanjay S Bhandari1,2,
  2. Prathap Kanagala1,2,
  3. Donald JL Jones1,2,3,
  4. Leong L Ng1,2
  1. 1Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
  2. 2NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, UK
  3. 3Department of Cancer Studies, Leicester Royal Infirmary, University of Leicester, Leicester, UK


Background Lipoproteins have an integral role in the pathogenesis of CAD. Quantitative proteomics is evolving to become an indispensable tool in the era of precision medicine. Using an unbiased lipoproteomic discovery workflow we sought to investigate the lipoproteomic differences between stable CAD patients and controls subjects and to reveal novel pathways/mechanisms that underpin this common disease.

Methods Male patients with stable CAD (n = 49, mean ± SD; age 64 yrs ± 8.69) and without CAD (n = 17; mean age 74 yrs ± 6.21) were recruited into this single centre prospective cohort study. Plasma was co-incubated with a lipophilic affinity resin. Isolated lipoproteins were reduced, alkylated, digested and analysed using label-free high definition ion mobility enabled mass spectrometry. Raw data was analysed using Progenesis QI software with a stringent false discovery rate of 1%.

Results 202 proteins showed significant differential expression between the CAD patients and the control subjects (P < 0.05). CAD patients had selective depletion of antioxidants; glutathione peroxidase 3 (GPX3) (p < 1e-28), clusterin (p < 1e-12) and serum paroxonase-1 (PON1) (p < 1e-7) compared with controls. Furthermore, there was selective up-regulation of proteins concerned with inflammation; serum amyloid A-1 (p < 1e-12), mannan binding lectin serine protease 1 (MASP1) (p < 1e-8) and galectin-3-binding protein (p = 0.001) in the CAD patients compared with the control subjects. Phospholipid transfer protein (PLTP) (p < 0.001) and apolipoprotein (a) (p = 0.002) were over expressed in the CAD patients.

Conclusion Patients with CAD have a distinct pathognomonic lipoproteomic cargo. The measurement of certain lipoprotein associated proteins may assist in the early identification of such patients before symptom onset.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.